Perucca Piero, Carter Jewell, Vahle Victoria, Gilliam Frank G
Department of Neurology, Columbia University, New York, NY, USA.
Neurology. 2009 Apr 7;72(14):1223-9. doi: 10.1212/01.wnl.0000345667.45642.61.
Adverse effects (AEs) of antiepileptic drugs (AEDs) are a major impediment to optimal dosing for seizure control. Better understanding of clinical properties of AEs is a prerequisite for systematic research of their neurobiological underpinnings. This study aimed to define specific patterns of AE occurrence and determine their clinical relevance based on their association with subjective health status.
Two hundred subjects with epilepsy completed validated self-report health assessments, including the Adverse Event Profile (AEP) and Quality of Life in Epilepsy Inventory (QOLIE)-89. Factor analysis was performed on the 19 AEP items to identify distinct classes of AEs. Correlations between AE class scores and QOLIE-89 scores were evaluated. Multivariate analysis was used to assess contributions of AE class scores to QOLIE-89 scores after controlling for depression and seizure frequency. Relationships between changes in AE class scores and changes in QOLIE-89 scores were also investigated in a subgroup of 62 subjects enrolled in a randomized trial.
The mean number of AEs per subject was 6.5. AEs were segregated into five classes: Cognition/Coordination, Mood/Emotion, Sleep, Weight/Cephalgia, and Tegument/Mucosa. Higher scores in each AE class were associated with lower QOLIE-89 scores. Cognition/Coordination scores were the strongest predictor of QOLIE-89 scores. Improvements in Cognition/Coordination, Mood/Emotion, and Tegument/Mucosa scores were associated with improvements in QOLIE-89 scores. Improved Cognition/Coordination was the only predictor of improved QOLIE-89.
Adverse effects (AEs) of antiepileptic drugs can be classified in five biologically plausible factors. When specific classes of AEs are identified and attempts are made to reduce them, quality of life is significantly improved.
抗癫痫药物(AEDs)的不良反应(AEs)是实现最佳癫痫控制剂量的主要障碍。更好地了解不良反应的临床特性是对其神经生物学基础进行系统研究的前提。本研究旨在确定不良反应发生的特定模式,并根据其与主观健康状况的关联来确定其临床相关性。
200名癫痫患者完成了经过验证的自我报告健康评估,包括不良事件概况(AEP)和癫痫患者生活质量量表(QOLIE)-89。对19项AEP项目进行因子分析,以识别不同类别的不良反应。评估了不良反应类别得分与QOLIE-89得分之间的相关性。在控制抑郁和癫痫发作频率后,使用多变量分析来评估不良反应类别得分对QOLIE-89得分的贡献。在一项随机试验的62名受试者亚组中,还研究了不良反应类别得分变化与QOLIE-89得分变化之间的关系。
每位受试者的平均不良反应数量为6.5。不良反应分为五类:认知/协调、情绪/情感、睡眠、体重/头痛和皮肤/黏膜。每个不良反应类别得分越高,QOLIE-89得分越低。认知/协调得分是QOLIE-89得分的最强预测因子。认知/协调、情绪/情感和皮肤/黏膜得分的改善与QOLIE-89得分的改善相关。认知/协调的改善是QOLIE-89改善的唯一预测因子。
抗癫痫药物的不良反应可分为五个生物学上合理的因素。当识别出特定类别的不良反应并试图减少它们时,生活质量会显著提高。